(Bloomberg) — Biotechnology stocks saw broad swings Friday morning as investors worked their way through a deluge of data from cancer drug developers presenting at the American Society of Clinical Oncology’s virtual annual meeting.Wall Street was quick to crown small-caps Adaptimmune Therapeutics Plc and Trillium Therapeutics Inc. as well as heavyweight AstraZeneca Plc among the early winners with shares rallying on the back of their respective updates. On the flip side, uninspiring results from Arvinas Inc.’s prostate cancer study and Aveo Pharmaceuticals Inc.’s kidney cancer trial drove investors to punish shares.Here’s a breakdown of some of ASCO’s biggest winners and …read more
Source:: Yahoo Finance
